MIRANDA MAMMEN: Open Payments
NPI 1912633926 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$408 in 21 payments from 10 companies in 2025. Trend: 2023 $603 · 2024 $527 · 2025 $408
Food & beverage: $408
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $214 |
| Novo Nordisk Inc | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Gilead Sciences, Inc. | 1 | $26 |
| Janssen Pharmaceuticals, Inc | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| PFIZER INC. | 1 | $15 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $14 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $14 |
| AstraZeneca Pharmaceuticals LP | 1 | $14 |
Products named: VRAYLAR, REXULTI, Wegovy, SPRAVATO, QULIPTA, Rybelsus, AZMIRO, NURTEC ODT.
Industry payments across NE — which companies pay providers there.
